Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | FLT3 |
Variant | R834Q |
Impact List | missense |
Protein Effect | gain of function |
Gene Variant Descriptions | FLT3 R834Q lies within the protein kinase domain of the Flt3 protein (UniProt.org). R834Q results in constitutive phosphorylation of Flt3, activation of Erk signaling, and is transforming in culture (PMID: 18068628). |
Associated Drug Resistance | |
Category Variants Paths |
FLT3 mutant FLT3 act mut FLT3 R834Q FLT3 mutant FLT3 exon20 FLT3 R834Q |
Transcript | NM_004119.3 |
gDNA | chr13:g.28018507C>T |
cDNA | c.2501G>A |
Protein | p.R834Q |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
NM_004119.2 | chr13:g.28018507C>T | c.2501G>A | p.R834Q | RefSeq | GRCh38/hg38 |
NM_004119 | chr13:g.28018507C>T | c.2501G>A | p.R834Q | RefSeq | GRCh38/hg38 |
NM_004119.3 | chr13:g.28018507C>T | c.2501G>A | p.R834Q | RefSeq | GRCh38/hg38 |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
FLT3 R834Q | Advanced Solid Tumor | sensitive | Midostaurin | Preclinical - Cell culture | Actionable | In a preclinical study, Rydapt (midostaurin) inhibited FLT3-induced phosphorylation of ERK1/2 and reduced growth of transformed cells expressing FLT3 R834Q in culture (PMID: 18068628). | 18068628 |
FLT3 R834Q | Advanced Solid Tumor | sensitive | PD98059 | Preclinical | Actionable | In a preclinical study, PD98059 inhibited ERK1/2 phosphorylation and reduced cell growth in transformed cells expressing FLT3 R834Q (PMID: 18068628). | 18068628 |
FLT3 R834Q | hematologic cancer | predicted - sensitive | Olverembatinib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells expressing FLT3 R834Q demonstrated decreased proliferation in response to Olverembatinib (HQP1351) in culture, but were less sensitive to treatment than cells expressing other FLT3 kinase domain mutations (PMID: 32247263). | 32247263 |